Home Other Building Blocks 9-(4'-AMINOPHENYL)-9H-PYRIDO[3,4-B]INDOLE

9-(4'-AMINOPHENYL)-9H-PYRIDO[3,4-B]INDOLE

CAS No.:
219959-86-1
Catalog Number:
AG00C29I
Molecular Formula:
Molecular Weight:
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG00C29I
Chemical Name:
9-(4'-AMINOPHENYL)-9H-PYRIDO[3,4-B]INDOLE
CAS Number:
219959-86-1
MDL Number:
MFCD01863339
IUPAC Name:
4-pyrido[3,4-b]indol-9-ylaniline
InChI:
InChI=1S/C17H13N3/c18-12-5-7-13(8-6-12)20-16-4-2-1-3-14(16)15-9-10-19-11-17(15)20/h1-11H,18H2
InChI Key:
CKJBUSARXRFUDR-UHFFFAOYSA-N
UNII:
NMC04J95OA
Properties
Complexity:
337  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
259.111g/mol
Formal Charge:
0
Heavy Atom Count:
20  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
259.312g/mol
Monoisotopic Mass:
259.111g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
43.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.2  
Literature
Title Journal
Role of human sulfotransferase 1A1 and N-acetyltransferase 2 in the metabolic activation of 16 heterocyclic amines and related heterocyclics to genotoxicants in recombinant V79 cells. Archives of toxicology 20170901
Analysis of an RNA adduct formed from aminophenylnorharman. Nucleic acids symposium series (2004) 20090101
Tumor-initiating potency of a novel heterocyclic amine, aminophenylnorharman in mouse colonic carcinogenesis model. International journal of cancer 20071015
Detection of aminophenylnorharman, a possible endogenous mutagenic and carcinogenic compound, in human urine samples. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20070101
Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymes expressed in Salmonella typhimurium umu tester strains. Mutagenesis 20061101
Lack of elevated liver carcinogenicity of aminophenylnorharman in p53-deficient mice. Cancer letters 20050120
Molecular nature of intrachromosomal deletions and base substitutions induced by environmental mutagens. Environmental and molecular mutagenesis 20050101
Carcinogenicity of aminophenylnorharman, a possible novel endogenous mutagen, formed from norharman and aniline, in F344 rats. Carcinogenesis 20041001
Identification of cytochrome P-450s involved in the formation of APNH from norharman with aniline. Mutation research 20040808
Potent genotoxicity of aminophenylnorharman, formed from non-mutagenic norharman and aniline, in the liver of gpt delta transgenic mouse. Carcinogenesis 20031201
Structure of DNA adduct formed with aminophenylnorharman, being responsible for the comutagenic action of norharman with aniline. Chemical research in toxicology 20021001
In vitro and in vivo formation of aminophenylnorharman from norharman and aniline. Mutation research 20020930
Induction of sister chromatid exchanges and chromosome aberrations in cultured mammalian cells treated with aminophenylnorharman formed by norharman with aniline. Mutation research 20020325
Maternal and developmental toxicity in mice by aminophenylnorharman, formed from norharman and aniline. Human & experimental toxicology 20020301
Testicular toxicity in F344 rats by aminophenylnorharman, formed from norharman and aniline. Toxicology and applied pharmacology 20010901
Oxidative DNA damage by an N-hydroxy metabolite of the mutagenic compound formed from norharman and aniline. Mutation research 20010725
Structures of mutagens produced by the co-mutagen norharman with o- and m-toluidine isomers. Mutation research 20010627
Induction of liver preneoplastic lesions by aminophenylnorharman, formed from norharman and aniline, in male F344 rats. Cancer letters 20010226
Properties